Stelara Clears FDA; Different Mechanism of Action, But REMS Looks Similar To TNF Class

Centocor's newest anti-inflammatory biologic - ustekinumab - actually has a different mechanism than the TNF inhibitors, but FDA has the sponsor using a risk management program similar to existing TNF drugs.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet